Literature DB >> 3395348

Apolipoprotein C-II deficiency: identification of a structural variant ApoC-II Padova.

S S Fojo1, G Baggio, C Gabelli, K Higuchi, M Bojanovski, R E Gregg, H B Brewer.   

Abstract

Apolipoprotein(apo) C-II DNA, RNA and protein from a patient with a familial deficiency of apoC-II were evaluated and compared to normal individuals. No major defect of the apoC-II gene could be detected by Southern blot hybridization. Northern and slot blot analyses of total liver RNA documented normal levels of a normal sized apoC-II mRNA. Immunohistochemical studies of the liver of the apoC-II deficient patient revealed a normal to slightly elevated intracellular content of the C-II apolipoprotein. Plasma apoC-II was 3 to 5% of normal apoC-II levels and exhibited abnormal electrophoretic mobility on two dimensional gel electrophoresis and immunoblotting. We postulate that at the molecular level, the deficiency of apoC-II in the plasma of this patient results from a structural defect in the coding portion of the apoC-II gene leading to either defective secretion of cellular apoC-II or increased catabolism of a structurally defective apoC-II in plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395348     DOI: 10.1016/0006-291x(88)90651-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Apo C-II deficiency type Bari.

Authors:  A Capurso; F Resta; F Turturro; A M Colacicco; C Crecchio; G Pepe
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

3.  Apolipoprotein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana.

Authors:  S Tuzgöl; S M Bijvoet; T Bruin; J J Kastelein; M R Hayden
Journal:  J Med Genet       Date:  1994-08       Impact factor: 6.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.